{"id":933218,"date":"2026-02-02T08:34:45","date_gmt":"2026-02-02T13:34:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/"},"modified":"2026-02-02T08:34:45","modified_gmt":"2026-02-02T13:34:45","slug":"polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/","title":{"rendered":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PARAMUS, NJ, Feb.  02, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c0lrNN9-aod6mdLBV_LrDa085ixNi22AeaerTIY9hLNnvd_spjl5o0q7KHvq-SXtiP1KgeeQnx1dc9oLvGTagwx88P3oMYdjExbTZkF3xDg=\" rel=\"nofollow\" target=\"_blank\">Polaryx Therapeutics<\/a> (\u201cPolaryx\u201d or the \u201cCompany\u201d) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (\u201cLSDs\u201d), announced that shares of the Company\u2019s common stock will start trading today on the Nasdaq Capital Market (\u201cNasdaq\u201d) under the ticker symbol \u201cPLYX\u201d.<\/p>\n<p>\u201cWe are pleased to announce that Polaryx\u2019s common stock will begin trading on the Nasdaq Stock Market today,\u201d said Alex Yang, Polaryx\u2019s Chairman and Chief Executive Officer. \u201cThis listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for devastating rare orphan lysosomal disorders. This achievement is also an important testament to the dedication and hard work of the entire Polaryx team.\u201d<\/p>\n<p>\u201cPolaryx is embarking on a pivotal and promising phase especially due to SOTERIA, our single arm, open-label Phase 2 trial with a planned launch in the first half of 2026. SOTERIA will assess our lead drug candidate PLX-200\u2019s safety, tolerability, and clinical activity for multiple indications within lysosomal storage disorder in a basket trial and represents a particularly unique, powerful and resource-efficient trial design and corporate catalyst.\u201d<\/p>\n<p>Maxim Group LLC acted as the exclusive financial advisor to Polaryx in connection with the direct listing. Gibson, Dunn &amp; Crutcher LLP served as legal advisor and Brownstein Hyatt Farber Schreck, LLP served as Nevada counsel.\u00a0<\/p>\n<p>\n        <b>About the SOTERIA Trial<\/b>\n      <\/p>\n<p>SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx\u2019s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200\u2019s future clinical development.\u00a0 Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the first half of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200\u2019s preclinical science across multiple LSDs while gathering data that will be invaluable in planning PLX-200\u2019s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200\u2019s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization.<\/p>\n<p>\n        <b>About Polaryx Therapeutics <\/b>\n      <\/p>\n<p>Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks to deliver safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share similar modes of action that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200\u2019s safety and efficacy. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5p_a0MPfXvUFrOPhcpOOClZboh66uMFa6LnlPgCDMBlqu1J5TzrUCbinbhvsE2HwgEcov1PNMulx6_xT2H3VvA==\" rel=\"nofollow\" target=\"_blank\">www.polaryx.com<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the federal securities laws, including, but not limited to, statements regarding: Polaryx\u2019s clinical development plans for PLX-200, including the timing for initiation of the SOTERIA trial. Words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cdevelop,\u201d \u201cplan\u201d or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Polaryx believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Polaryx\u2019s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company\u2019s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Polaryx\u2019s clinical trials; expectations regarding the timing, completion and outcome of Polaryx\u2019s clinical trials; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Polaryx\u2019s Registration Statement on Form S-1, as amended, filed with the SEC on January 27, 2026 and subsequent disclosure documents Polaryx may file with the SEC. Polaryx claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Polaryx expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <b>Media Contact:<\/b><br \/>\n        <br \/>Jules Abraham<br \/>Managing Director, Communications<br \/>CORE IR<br \/>(212) 655-0924<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ltowQzmLmHKGrfxzWSm9w--44gtnPZg4RBZJQ5nAIOdeaDyAqFBFN7TiNrdfYEXa73ngoUkjZDnCZoeqvgWO1Hrvf4vPpthJEOtRrrn6BZg=\" rel=\"nofollow\" target=\"_blank\">Julesa@coreir.com<\/a><\/p>\n<p>\n        <b>Investor Contacts:<\/b><br \/>\n        <br \/>CORE IR<br \/>(212) 655-0924<br \/>investor@polaryx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjdlODg2YjEtYWFkNC00NDgwLWFjNDAtMTgwMjJiZWNiNTZmLTUwMDE1Njg1Mi0yMDI2LTAyLTAyLWVu\/tiny\/Polaryx-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) &#8212; Polaryx Therapeutics (\u201cPolaryx\u201d or the \u201cCompany\u201d) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (\u201cLSDs\u201d), announced that shares of the Company\u2019s common stock will start trading today on the Nasdaq Capital Market (\u201cNasdaq\u201d) under the ticker symbol \u201cPLYX\u201d. \u201cWe are pleased to announce that Polaryx\u2019s common stock will begin trading on the Nasdaq Stock Market today,\u201d said Alex Yang, Polaryx\u2019s Chairman and Chief Executive Officer. \u201cThis listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933218","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) &#8212; Polaryx Therapeutics (\u201cPolaryx\u201d or the \u201cCompany\u201d) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (\u201cLSDs\u201d), announced that shares of the Company\u2019s common stock will start trading today on the Nasdaq Capital Market (\u201cNasdaq\u201d) under the ticker symbol \u201cPLYX\u201d. \u201cWe are pleased to announce that Polaryx\u2019s common stock will begin trading on the Nasdaq Stock Market today,\u201d said Alex Yang, Polaryx\u2019s Chairman and Chief Executive Officer. \u201cThis listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for &hellip; Continue reading &quot;Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T13:34:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d\",\"datePublished\":\"2026-02-02T13:34:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/\"},\"wordCount\":944,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/\",\"name\":\"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\",\"datePublished\":\"2026-02-02T13:34:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/","og_locale":"en_US","og_type":"article","og_title":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk","og_description":"PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) &#8212; Polaryx Therapeutics (\u201cPolaryx\u201d or the \u201cCompany\u201d) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (\u201cLSDs\u201d), announced that shares of the Company\u2019s common stock will start trading today on the Nasdaq Capital Market (\u201cNasdaq\u201d) under the ticker symbol \u201cPLYX\u201d. \u201cWe are pleased to announce that Polaryx\u2019s common stock will begin trading on the Nasdaq Stock Market today,\u201d said Alex Yang, Polaryx\u2019s Chairman and Chief Executive Officer. \u201cThis listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for &hellip; Continue reading \"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-02T13:34:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d","datePublished":"2026-02-02T13:34:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/"},"wordCount":944,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/","name":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==","datePublished":"2026-02-02T13:34:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NjExNiM3NDAxNDc5IzUwMDE1Njg1Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol \u201cPLYX\u201d"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933218"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933218\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}